Jeffrey N. Simmons, President and CEO of Elanco Animal Health (ELAN), has demonstrated a clear selling bias in his recent insider transactions, with $7.01 million in total sales compared to $752,432 in purchases across 32 reported trades. His most significant transactions include a $6.07 million sale on March 1, 2026, and a $942,902 sale on March 3, 2026, both coded as derivative dispositions (Code F). These large-scale disposals contrast sharply with his smaller, routine acquisitions—primarily coded as open market purchases (Code A)—which consistently amounted to $2,769.24 per transaction through late 2025 and early 2026, with occasional variations like the $105,064 purchases on March 6, 2026.
Simmons’ trading activity is exclusively concentrated in Elanco, reflecting his executive role at the company. The pattern shows sustained selling pressure in early 2026, particularly through derivative transactions, while maintaining smaller, periodic open market buys. The absence of recent sales in the latest filings—only a single buy recorded on March 20, 2026, valued at $2,826.93—suggests a potential shift in behavior, though the broader trend remains weighted toward divestment. The transactions provide a transparent view of his equity adjustments without implying any undisclosed corporate developments.
AI-assisted summary